MAP Pharmaceuticals has appointed W. James O’Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O’Shea held a number of positions in operations and commercialization and had previously worked for Zeneca Pharmaceuticals, including as Senior VP of Sales and Marketing and Medical Affairs.
MAP is preparing for the launch of its Levadex inhaled dihydroergotamine for the treatment of migraine if approved by the FDA. Shortly after filing the NDA in August 2011, hired Frederick Graff, a former Sepracor VP of Sales as VP of Commercial Operations, and MAP says that O’Shea’s appointment is also intended to support the launch. The goal date for the Levadex NDA is March 26, 2012.
MAP President and CEO Timothy S. Nelson commented, “We are privileged to welcome Jim to our Board of Directors at this exciting time in the Company’s development as we focus our efforts on building a commercial infrastructure to support the launch and commercialization of Levadex, if approved. The depth of Jim’s experience in commercializing new pharmaceutical products in specialist markets will provide great value and we look forward to benefitting from his expertise as we advance Levadex.”
Read the MAP press release.
